Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Assessment of Minimal Residual Disease in Standard-Risk AML (NPM1)

Persistence of NPM1-mutated transcripts in blood after the second chemotherapy cycle was present in 15% of patients and was associated with a greater 3-year relapse risk than absence of transcripts (82% vs 30%; HR 4.80, 95% CI 2.95-7.80, P<0.001) and lower survival (24% vs 75%; HR for death 4.38, 95% CI 2.57-7.47, P<0.001). MRD was the only independent prognostic factor for death in multivariate analysis (HR 4.84, 95% CI 2.57-9.15, P<0.001). Level 2. Foundational NPM1 MRD paper.

N Engl J MedPubMed 26789727